Entries by Uta Mommert

Epigenomics considers US listing

Back in April, the American FDA gave the green light for the colorectal cancer-screening test Epi procolon. Now Berlin-based diagnostics specialist Epigenomics is considering a secondary listing in the US. A draft of the required registration document was confidentially submitted to the US Securities and Exchange Commission (SEC). 

Genmab in HIV antibody deal

Danish Genmab AS has granted Gilead Sciences license to use its DuoBody technology platform to develop bispecific antibodies for the treatment of HIV. The deal is worth up to €252m.

Ploughing ahead after Phase III setback

Hungarian Gedeon Richter and Irish Allergan are staying on course in the face of dissappointing Phase III results for depression drug cariprazine. The partners will now begin another Phase III study needed for approval.

Alzheimer’s vaccine clears Phase I

Araclon Biotech’s Alzheimer’s vaccine ABvac40 is going forward into Phase II after showing a good safety profile in Phase I. The promising trial results were presented at the Alzheimer’s Association International Conference. 

EMA keeps approval speedway open

After a two-year pilot period, the EMA has published its report on its adaptive pathways approach. The agency plans to explore the concept further and will continue to accept proposals.

Inflammation spin-off launched

Life science venture capital group Epidarex has launched Nodthera Ltd, a biotech based on research by Poland-based drug discovery company Selvita. The start-up aims to develop novel inhibitors of the NLRP3 inflammasome. 

GSK picks up asthma mAb

GlaxoSmithKline has in-licensed Janssen’s anti-IL-33R monoclonal antibody for severe asthma. The British drugmaker is paying €208m up front for the mAb.

Brexit: calls for reassurance

In view of the Brexit, research academies across Britain are calling for a bold commitment from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

JANUS® G3 Automation Workstations

JANUS® Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 ?l to 5000 ?l for consistent and reproducible sample preparation